Clinical trial · Observational
DNA Mutation Detection in Circulating Tumor DNA and Tissue by mmADPS for Pancreatic Cancer
DNA Mutation Detection in Circulating Tumor DNA and Tissue by Massive Multiplex Allele Discrimination Priming System(mmADPS) for Pancreatic Cancer
NCT05604573CI-TRIAL-00061915unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Based on the cell free nucleic acid analysis information of blood samples and genetic mutation profile of EUS-FNB tissue from pancreatic cancer, the concordance between them is evaluated. And based on this information, biomarkers for diagnosis, treatment, and prognosis of pancreatic cancer are explored.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cell free DNA in blood, genetic mutation in tissue | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- pancreatic cancer
- description
- patients with pancreatic cancer
- interventionNames
- Diagnostic Test: cell free DNA in blood, genetic mutation in tissue
- label
- control
- description
- patients without any malignancy
- interventionNames
- Diagnostic Test: cell free DNA in blood, genetic mutation in tissue
Primary outcomes (2)
- measure
- correlation of genetic mutation
- timeFrame
- the day of study enrollment (baseline)
- description
- concordance of genetic mutation between tissue and blood of treatment-naive status
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with pancreatic cancer through histological or radiologic examination and before treatment begins * Patients aged 18 or older who voluntarily agrees to participate in the study and is willing to understand and comply with the subsequent treatment procedures and sample collection schedule * Among patients diagnosed with benign pancreatic diseases (pancreatic cyst, chronic pancreatitis, etc.), patients who have need for histological examination as control group Exclusion Criteria: * Where the subject himself/herself refuses to fill out the consent form or is unable to fill out the consent form * If a laboratory test is impossible due to a qualitative problem with the collected blood sample * Where the collected tissue does not contain tissue of the desired malignant or benign disease
References
Publications (0)
Data not yet available
No reference posted for this study.